tDCS to Decrease Opioid Relapse (UH3)
ConditionOpioid Use Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-60
SponsorButler Hospital
About this trial
Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.
Eligibility criteria
Qualifiers
current opioid dependence
between 21-60 years of age
recent initiation of buprenorphine or methadone (≤90 days)
enrolled in Butler Hospital's Alcohol and Drug Inpatient Unit, Alcohol and Drug Partial Hospital Treatment Program, Intensive Outpatient Services, or Outpatient Services at Butler Hospital OR receive opioid-treatment services in the community.
Disqualifiers
current diagnosis of organic brain disorder (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis, intracranial mass/infection, hydrocephalus)
bipolar, schizophrenia, schizoaffective, or schizophreniform disorder, or current psychosis associated with any disorder
current suicidality
evidence of significant neurocognitive dysfunction
Trial design
Treatments tested in this trial
- active tDCS
- sham tDCS
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Butler Hospital
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov